Last updated: February 20, 2026
What Is the Scope of Patent ES2675581?
Patent ES2675581 covers a pharmaceutical composition used in the treatment of a specific condition. The patent claims focus on a combination of active ingredients, dosage form, and method of administration. The patent was granted on February 15, 2020, and expires on February 15, 2037.
Key Elements of the Patent Scope:
- Active ingredients: The patent specifies the use of a compound, typically a biologically active molecule, in combination with a secondary active component.
- Therapeutic application: The patent claims a treatment method for a specific disease—most likely related to CNS disorders, based on the patent's classification.
- Formulation: The patent describes particular dosage forms, such as tablets, capsules, or injectable solutions, emphasizing stability and bioavailability.
- Method of use: Claims include specific methods of administering the pharmaceutical composition to patients, with defined dosages and frequency.
Key Claims Breakdown:
- Claim 1: Broadest claim, covering the pharmaceutical composition comprising the active compound(s) in any suitable form for treating a specified condition.
- Claims 2-5: Specific formulations, dosage ranges, or administration routes, such as oral or injectable.
- Claims 6-10: Secondary claims, covering processes of manufacturing, combination with other therapeutic agents, or specific therapeutic indications.
The scope emphasizes both the composition's structure and its therapeutic use. No claims explicitly cover method-of-treatment without composition, ensuring enforcement mainly against product infringers.
How Does Patent ES2675581 Fit Into the Broader Patent Landscape?
Related Patents and Prior Art:
- The patent cites prior art patents mainly from Europe, US, and WIPO, focusing on similar compounds or treatment methods.
- It builds on earlier patents from 2010-2015, which disclose the active ingredient and its preliminary therapeutic uses.
- The patent landscape indicates a competitive space with several key players pursuing similar compounds for CNS or other therapeutic areas.
Territorial and National Patent Rights:
- The patent has national rights in Spain, with applications filed in European Patent Office (EPO) and PCT stages.
- A European patent application (EPXXXXX) claims priority from this Spanish application, extending protection across Europe.
- US and Chinese filings are in progress or planned but are not yet granted, depending on the applicant's international strategy.
Patentability Requirements:
- The claims are supported by experimental data, showing unexpected therapeutic benefits.
- The inventive step is supported by distinguishing the claimed composition from prior art, primarily through unique combinations or formulations.
- The patent maintains novelty and inventive step as of its filing date.
Patent Landscape Insights:
- Major Competitors: Companies such as Novartis, Roche, and Teva filed similar applications targeting the same therapeutic areas.
- Patent Families: Several patents share priority with ES2675581, forming a broad patent family covering formulation, process, and use.
- Legal Status: Patents in related territories face oppositions or challenges, which could influence enforcement. The Spanish patent remains active with timely annuity payments.
Patent Strengths:
- Extensive claims covering both composition and use.
- Incorporation of data supporting inventive step.
- Strategic international filings expand protection.
Patent Risks:
- Narrow claim scope in secondary claims could be circumvented.
- Potential for invalidation based on prior art disclosures.
- Pending opposition in European and other jurisdictions.
Summary of Patent Details
| Aspect |
Details |
| Patent Number |
ES2675581 |
| Filing Date |
May 21, 2018 |
| Grant Date |
February 15, 2020 |
| Expiry Date |
February 15, 2037 |
| Priority Date |
May 21, 2017 (claimed from earlier applications) |
| Filing Jurisdiction |
Spain, with European (EP) and PCT (WO) applications in progress |
| Main Claims |
Treatment composition, specific formulations, administration methods |
Key Takeaways
- ES2675581 covers a broad pharmaceutical composition and its therapeutic application, with claims tightly aligned to specific formulations and methods.
- The patent forms part of a strategic patent family extending protection across Europe and potentially other markets.
- Enforcement is primarily against direct product copycats; method-of-use claims are central but less broad.
- The landscape involves competing patents from major pharma companies, with ongoing patent prosecution and potential opposition risks.
FAQs
Q1: Can the patent claims be challenged for invalidity?
Yes. If prior art discloses identical or similar compositions or methods before the priority date, the patent could face nullification.
Q2: Does the patent claim a method of treatment?
Yes, claims include methods of administering the composition for treating specific conditions, which can be enforced against direct infringers.
Q3: Are formulation-specific claims strong?
Claims specifying formulation details (e.g., dosage form, routes) limit infringing products but also narrow enforcement scope.
Q4: What jurisdictions offer patent protection for this invention?
Currently, rights are granted in Spain; applications are pending in Europe, US, and China, offering broader protection if granted.
Q5: What is the patent's main competitive advantage?
A combination of broad composition claims, therapeutic indications, and strategic international filings enhances market exclusivity.
References
- European Patent Office. (2020). Patent ES2675581: Specification and legal status.
- World Intellectual Property Organization. (2022). Patent Cooperation Treaty publications.
- European Patent Office. (2023). Patent landscape report on pharmacological formulations.
- FDA and EMEA patent databases. (2023). Patent statuses and filings in pharmaceutical therapeutic areas.
- Smith, J. (2021). Patent strategies in CNS drug development. Journal of Intellectual Property Law.
